Investigation of c-myc and p53 gene alterations in the tumor and surgical borderline tissues of NSCLC and effects on clinicopathologic behavior: By the FISH technique

被引:15
作者
Yakut, T [1 ]
Egeli, U
Gebitekin, C
机构
[1] Univ Uludag, Dept Med Biol & Genet, Bursa, Turkey
[2] Univ Uludag, Fac Med, Dept Thorac Surg, Bursa, Turkey
关键词
NSCLC; c-myc; p53; FISH; surgical borderline;
D O I
10.1007/s00408-003-1026-x
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Genetic alterations on the primary tumoral tissues and surgical borderline tissues of 51 patients with NSCLC on which radiotherapy and chemotherapy had not been performed were analyzed by using the FISH method with locus-specific probes for p53 tumor suppressor gene and c-myc oncogene and centromere-specific probes for chromosome 17 and chromosome 8 on which these genes are located. P53 deletions were detected in 7 patients (13.7%), c-myc amplification in 4 patients (7.8%), monosomy 17 in 2 patients (3.9%) and trisomy 8 in 3 patients (5.8%), and a high level of polyploidy in tumoral tissues of 6 patients (11.7%). P53 deletion and c-myc amplification were found at surgical borderlines of 2 patients and I patient, respectively. Although both p53 deletion and c-myc amplification have low frequency at surgical border tissues, not only their detection is important for the follow-up of recurrency and metastasis, but it is also important for genetical and pathological staging. The results of this study show that c-myc amplification in NSCLC is related to the shortening of survival (p < 0.01). C-myc amplification and p53 deletion are also effective for the occurrence of metastasis (p < 0.05) and the effect of c-myc amplification in this matter is much higher than p53 deletion. The gain or loss of copy number of chromosome 8 and monosomy 17 show parallel effects with c-myc amplification and p53 deletion, respectively, on the clinicopathological behavior of tumors.
引用
收藏
页码:245 / 258
页数:14
相关论文
共 37 条
[1]   MOLECULAR ASSESSMENT OF HISTOPATHOLOGICAL STAGING IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].
BRENNAN, JA ;
MAO, L ;
HRUBAN, RH ;
BOYLE, JO ;
EBY, YJ ;
KOCH, WM ;
GOODMAN, SN ;
SIDRANSKY, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (07) :429-435
[2]  
CHEN S, 2001, CANC LETT, V162, P5
[3]   Molecular biologic substaging of stage I lung cancer according to gender and histology [J].
D'Amico, TA ;
Aloia, TA ;
Moor, MBH ;
Herndon, JE ;
Brooks, KR ;
Lau, CL ;
Harpole, DH .
ANNALS OF THORACIC SURGERY, 2000, 69 (03) :882-886
[4]   TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis [J].
deAnta, JM ;
Jassem, E ;
Rosell, R ;
MartinezRoca, M ;
Jassem, J ;
MartinezLopez, E ;
Monzo, M ;
SanchezHernandez, JJ ;
Moreno, I ;
SanchezCespedes, M .
ONCOGENE, 1997, 15 (24) :2951-2958
[5]  
DosakaAkita H, 1997, CANCER-AM CANCER SOC, V79, P1329, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1329::AID-CNCR9>3.0.CO
[6]  
2-B
[7]  
EKMEKCI A, 1991, TDFO 72, P57
[8]  
Fontanini G, 1996, CLIN CANCER RES, V2, P1067
[9]   P53 GENETIC ABNORMALITIES AND MYC ACTIVATION IN HUMAN LUNG-CARCINOMA [J].
GAZZERI, S ;
BRAMBILLA, E ;
DEFROMENTEL, CC ;
GOUYER, V ;
MORO, D ;
PERRON, P ;
BERGER, F ;
BRAMBILLA, C .
INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (01) :24-32
[10]   Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies [J].
Huncharek, M ;
Kupelnick, B ;
Geschwind, JF ;
Caubet, JF .
CANCER LETTERS, 2000, 153 (1-2) :219-226